Blog

The ability to detect ovarian cancer in its early stages continues to elude researchers. Cheng Wang, PhD, is determined to change that.

Study highlights the pitfalls of basing clinical recommendations on data heavily skewed towards one race or ethnic group.

A new method for harvesting bone marrow stem cells for transplant could be a game changer.

In the 12 days leading up to our holiday hiatus, we are looking back on the past year and sharing some highlights in Massachusetts General Hospital research news from each month of 2017.

In the 12 days leading up to our holiday hiatus, we are looking back on the past year and sharing some highlights in Massachusetts General Hospital research news from each month of 2017.

Imagine enduring a painful, expensive and scar-inducing surgery—only to find out afterwards that it wasn’t necessary. This is the situation for many women with high-risk breast lesions.

Unfortunately, a third of cancer patients who receive chemotherapy encounter this as a side effect, a condition known as chemotherapy-induced peripheral neuropathy (CIPN). This neuropathy is a result of nerve damage or impairment of the nervous system and often is chronic.

Researchers have been looking for a safe, fast, less expensive and more accurate way to identify early signs of treatment resistance, while also searching for new insights into the genetic changes that occur within tumor cells to drive this resistance. This way, new therapy plans can be considered sooner, giving the patient a better chance for their best possible outcome.

In a case of mistaken identity, researchers at Massachusetts General Hospital have found that lymph nodes are not always responsible for cancer’s deadly progression to other organs.

At Massachusetts General Hospital, a real-life Trojan horse scenario that takes place on the nanoscale level could provide a way to sneak cancer drugs into fortified tumor cells so the drugs can attack from within.